Adenosintriphosphate sodium (Solution) Instructions for Use
ATC Code
C01EB10 (Adenosine)
Active Substance
Triphosadenine (DCF adopted for use in France)
Clinical-Pharmacological Group
Drug improving metabolism of the myocardium, used for paroxysmal supraventricular tachyarrhythmias
Pharmacotherapeutic Group
Metabolic agent
Pharmacological Action
A means of improving metabolism and energy supply to tissues. ATP is a natural component of body tissues and is involved in many metabolic processes.
When ATP breaks down into ADP and inorganic phosphate, energy is released that is necessary for muscle contraction and various biochemical processes.
ATP is involved in the transmission of excitation in adrenergic and cholinergic synapses and facilitates the transmission of excitation from the vagus nerve to the heart.
Apparently, ATP is one of the mediators that excite adenosine receptors.
It enhances cerebral and coronary circulation and promotes an increase in peripheral circulation.
Triphosadenine is a derivative of adenosine.
Adenosine is an agonist of purinergic receptors, the activation of which leads to inhibition of depolarization of the processes of conduction of electrical impulses in the sinus and AV nodes.
This effect underlies the antiarrhythmic action of triphosadenine in supraventricular tachycardias.
It acts briefly for a few seconds.
Pharmacokinetics
After parenteral administration, it penetrates into the cells of organs, where it is broken down into adenosine and inorganic phosphate with the release of energy. Subsequently, the breakdown products are included in the resynthesis of ATP.
Indications
Relief of paroxysms of supraventricular tachycardia (excluding atrial fibrillation and/or flutter).
ICD codes
| ICD-10 code | Indication |
| I47.1 | Supraventricular tachycardia |
| ICD-11 code | Indication |
| BC81.0 | Ectopic atrial tachycardia |
| BC81.1 | Nodal ectopic tachycardia |
| BC81.20 | CTI [cavotricuspid isthmus]-dependent atrial tachycardia by "macro re-entry" mechanism |
| BC81.21 | Atrial tachycardia by "macro re-entry" mechanism not associated with scar or cavotricuspid isthmus |
| BC81.2Z | Atrial tachycardia by "macro re-entry" mechanism, unspecified |
| BC81.5 | Sinoatrial reentrant tachycardia |
| BC81.7Z | Atrioventricular reentrant tachycardia, unspecified |
| BC81.8 | Atrioventricular nodal reentrant tachycardia |
| BC81.Z | Supraventricular tachyarrhythmia, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer intravenously as a rapid bolus injection over 1-2 seconds directly into a vein or through an intravenous line. Use a large proximal vein, such as the antecubital vein, to minimize local discomfort.
For adult patients, the initial dose is 6 mg. If the first dose does not result in termination of the supraventricular tachycardia within 1-2 minutes, administer a second dose of 12 mg.
If the 12 mg dose is ineffective, a third and final dose of 18 mg may be administered after 1-2 minutes. Do not exceed a single dose of 18 mg or a total cumulative dose of 30 mg.
Follow each bolus injection immediately with a rapid 0.9% sodium chloride flush to ensure the drug reaches the systemic circulation. Have resuscitation equipment readily available during administration due to the potential for serious adverse effects.
For patients taking dipyridamole, reduce the initial dose to 3 mg or less due to potentiated effects. For patients with heart transplant, use a lower initial dose of 3 mg or less, as they may be hypersensitive to the drug’s effects.
Do not administer more than two doses for a single episode of tachycardia without consulting a specialist. This drug is intended for hospital or clinical settings with continuous ECG and blood pressure monitoring.
Adverse Reactions
With intramuscular administration, headache, tachycardia, increased diuresis, hyperuricemia are possible.
With intravenous administration, nausea, facial skin hyperemia, headache, weakness are possible.
Allergic reactions rarely – itching, skin hyperemia.
Contraindications
Acute myocardial infarction, severe arterial hypotension, severe bradycardia, sick sinus syndrome, second- or third-degree AV block (except for patients with an artificial pacemaker), acute and chronic heart failure in the stage of decompensation, COPD, bronchial asthma, long QT syndrome, pregnancy, breastfeeding period, age under 18 years, hypersensitivity to triphosadenine.
With caution
Bradycardia, first-degree AV block, bundle branch block, atrial fibrillation and flutter, arterial hypotension, coronary artery disease, hypovolemia, pericarditis, heart valve stenosis, left-to-right arteriovenous shunt, cerebrovascular insufficiency, conditions after heart transplantation (less than 1 year).
Use in Pregnancy and Lactation
Contraindicated for use during pregnancy and breastfeeding.
Pediatric Use
Contraindicated for use in children and adolescents under 18 years of age.
Geriatric Use
Use with caution in elderly patients.
Special Precautions
Simultaneous use of triphosadenine and cardiac glycosides in high doses is not recommended.
Drug Interactions
With simultaneous use with cardiac glycosides, the risk of side effects (including arrhythmogenic action) increases.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Solution for intravenous administration 10 mg/1 ml: amp. 10 pcs.
Marketing Authorization Holder
Microgen NPO, JSC (Russia)
Dosage Form
 |
Adenosintriphosphate sodium | Solution for intravenous administration 10 mg/1 ml: amp. 10 pcs. |
Dosage Form, Packaging, and Composition
| Solution for intravenous administration | 1 amp. |
| Triphosadenine (sodium adenosinetriphosphate) | 10 mg |
1 ml – ampoules (10) – cardboard packs.
Solution for intravenous administration 10 mg/ml: amp. 1 ml 5 or 10 pcs.
Marketing Authorization Holder
Ellara, LLC (Russia)
Dosage Form
|
Adenosintriphosphate sodium | Solution for intravenous administration 10 mg/ml: amp. 1 ml 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
Solution for intravenous administration colorless or slightly yellowish, transparent.
| 1 ml | |
| Triphosadenine* | 10 mg |
* disodium adenosinetriphosphate dihydrate in terms of adenosinetriphosphoric acid.
Excipients: sodium carbonate anhydrous – 4.4 mg, sodium bicarbonate – 8 mg, disodium edetate dihydrate – 0.2 mg, propylene glycol – 0.1 mg, water for injection – up to 1 ml.
1 ml – ampoules (5) – cardboard packs.
1 ml – ampoules (10) – cardboard packs.
1 ml – ampoules (5) – contour cell packs made of polyvinyl chloride film (1) – cardboard packs.
1 ml – ampoules (5) – contour cell packs made of polyvinyl chloride film (2) – cardboard packs.
1 ml – ampoules (5) – contour cell packs made of polyvinyl chloride film (4) – cardboard packs (for hospitals).
1 ml – ampoules (5) – contour cell packs made of polyvinyl chloride film (5) – cardboard packs (for hospitals).
1 ml – ampoules (5) – contour cell packs made of polyvinyl chloride film (10) – cardboard packs (for hospitals).
1 ml – ampoules (5) – contour cell packs made of polyvinyl chloride film (50) – cardboard packs (for hospitals).
1 ml – ampoules (5) – contour cell packs made of polyvinyl chloride film (100) – cardboard packs (for hospitals).
Solution for intravenous administration 1% (10 mg/1 ml): amp. 5 pcs.
Marketing Authorization Holder
Darnitsa Pharmaceutical Firm, PJSC (Ukraine)
Dosage Form
|
Adenosintriphosphate sodium-Darnitsa | Solution for intravenous administration 1% (10 mg/1 ml): amp. 5 pcs. |
Dosage Form, Packaging, and Composition
| Solution for intravenous administration 1% | 1 amp. |
| Triphosadenine (sodium adenosinetriphosphate) | 10 mg |
1 ml – ampoules (5) – cardboard packs.
![Adenosintriphosphate sodium [Solution] 1](https://www.medixlife.com/wp-content/uploads/Medixlife_favi_512.png "Adenosintriphosphate sodium [Solution] 2")